Biotech Values

[DewDiligence]

IDIX—It doesn't seem to me that the IDX899 compound is considered and or appreciated by those covering IDIX when it comes to valuation.

I agree and I think there’s an explanation: Until recently, most investors thought GILD owned the HIV market lock, stock, and barrel. A corollary: these investors thought no company had a chance to gain any traction in HIV unless it was working directly with GILD. IDIX’s partner, GSK, was considered a hopeless also-ran in HIV.

These views appear to finally be softening to some degree. Most investors still think non-GILD HIV programs face long odds, but there’s a growing recognition, IMO, that other companies have a shot if they play their cards right. GSK’s program for the integrase inhibitor, ‘572, is case in point (#msg-52482079).